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Case presentation
A 40-year-old white male, an insurance company executive, was
found to have a blood pressure of 160/95 mm Hg during a hypertension
screening program at his workplace. He was told to see his family
physician for follow-up care. One week later his blood pressure was
165/94 mm Hg in both arms, and no postural changes were noted.
Physical examination revealed a mildly obese but otherwise healthy
appearing white male weighing 79.5 kg; the eyegrounds showed grade-I
hypertensive changes. Cardiovascular examination was normal, and no
abdominal or carotid bruits were noted.
The medical history revealed that the patient's blood pressure had
been "normal" on most previous examinations, but that he occasional-
ly had been told of mild elevations. The physician had said that the
stress of the examination probably caused the elevation in blood
pressure but that his blood pressure ought to be measured periodically.
The patient denied any history suggestive of catecholamine excess,
hypokalemia, or renal disease. He denied ingesting any medications
other than an occasional aspirin. He had smoked one pack of cigarettes
daily for 20 years, and he assiduously avoids any formal physical
exercise. His father was known to be hypertensive and took medica-
tions for many years before dying at age 58 of an acute myocardial
infarction. His mother is alive and well in her 80s; he has no siblings.
Laboratory studies revealed normal values for serum electrolytes,
creatinine, BUN, and blood glucose. Complete blood count and urinal-
ysis were entirely within normal limits. Serum cholesterol was 320 mg/
dl, and a 24-hour urine collection contained 210 mEq of sodium;
creatinine clearance was normal. Electrocardiogram and chest x-ray
were normal.
His blood pressure was measured biweekly over the ensuing 2
months by a nurse at the company dispensary. Values ranged from 150—
165/93—100 mm Hg. A graduated exercise program, weight reduction,
and modest salt restriction (75 mmol NaC1 daily) were proposed.
Three months later the patient admitted a continuing interest in
spectator sports but not participatory exercise, he gained 2 pounds, and
he guiltily admitted an inability to reduce his salt intake. His blood
pressure at the time was 160/94 mm Hg. At that time, therapy with 25
mg daily of hydrochlorothiazide was begun. Over the next 2 months his
blood pressure ranged from 120—130/85—90 mm Hg.
Discussion
DR. ROBERT G. NARINS (Chief, Nephrology Section, and
Professor of Medicine, Temple University Health Sciences
Center, Philadelphia, Pennsylvania): Debate currently rages
over whether pharmacologic treatment of mild hypertension, as
in the patient under discussion today, results in net long-term
clinical benefit [1—9]. Current estimates suggest that approxi-
mately 60 million Americans are hypertensive and that two-
thirds, or 40 million people, have "mild hypertension" with
diastolic blood pressure (DBP) in the range of 90 to 104 mm Hg.
Given the magnitude of the affected population, prevention of
even a small percentage of hypertension-induced morbidity and
mortality by chemotherapy would benefit hundreds of thou-
sands. Conversely, if antihypertensive drugs were unable to
substantially alter the natural history of mild hypertension,
many millions would be needlessly exposed to the appreciable
expense and potential toxicity of these agents. The socioeco-
nomic and public health ramifications of this therapeutic dilem-
ma are enormous. The ensuing discussion attempts both to
critically review and to put into practical perspective the data
bearing on whether mild hypertension is dangerous and, if it is,
whether antihypertensive agents improve its overall prognosis.
Although now taken for granted, the use of chemotherapy for
even the most severe degrees of hypertension is actually less
than 30 years old! Keith et al in 1939 and Kincaid-Smith and
coworkers in 1959 clearly demonstrated that more than 90% of
patients with untreated malignant hypertension were dead
within one year of diagnosis [10, 11]. Whereas sympathectomy
and unilateral nephrectomy prolonged survival in isolated cas-
es, the advent and use of orally effective, relatively safe,
antihypertensive agents quickly demonstrated that survival
could be consistently and dramatically improved [12] (Fig. 1).
The efficacy of these agents in the setting of malignant hyper-
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Fig. 1. Effect of therapy on survival in malignant hypertension. See text
for details. (Reproduced with permission from Hamngton et a! [121.)
tension was rapidly and universally accepted, and no cries for
controlled studies were heard.
Would chronic lowering of lesser degrees of hypertension
also prove beneficial or would the recognized increased inci-
dence of stroke and heart and kidney failure continue unabated?
Indeed, many questioned whether such therapy would compro-
mise organ perfusion, arguing that increased hydrostatic pres-
sure might be required to sustain normal blood flow through
damaged and stenotic vessels. Others suggested that drug
toxicity might negate any benefits derived from pharmacologic
lowering of blood pressure. Because it took longer for severe
but non-malignant hypertension to manifest its putative conse-
quences, and because a smaller percentage of the population at
risk was overtly affected, it became clear that carefully con-
trolled prospective studies were needed. In 1967, the first of the
landmark Veteran's Administration cooperative studies was
published; this study clearly demonstrated the benefits of
chemotherapy in subjects with non-malignant but severe hyper-
tension (DBP, 115—129 mm Hg) [131. Results from this random-
ized, double-blind, placebo-controlled trial showed that the
untreated group (N = 70) developed 23 morbid events and 4
deaths in less than 1.5 years, as compared with the drug-treated
group (N = 73), which manifested only 2 such events and no
deaths (Table 1).
Once again, the study of a severe, life-threatening disorder
allowed a simple short-term investigation to quickly and un-
equivocally demonstrate the benefits of drug therapy. In 1970
this same group, using a similar protocol, evaluated the effects
of antihypertensive treatment in patients with DBPs ranging
from 105 to 114 mm Hg [14]. Eighty-six of the 170 subjects
Table 1. Veterans Administration Cooperative Study: Effect of
antihypertensive therapy on morbidity/mortality
(DBP 115—129mm Hg)
Mortality
Drug 0
Placebo 4 3 Aortic aneurysms
1 Sudden death
Morbidity
Drug
re-
action AMIa CHF CVA
Ris-
ing
BUN
Ris-
ing
BP
Worsen-
ing
retino-
pathy Total
Drug 1 1 2
Placebo 2 4 4 3 3 7 23
P < .001
a AMI, acute myocardial infarction; CHF, congestive heart failure;
CVA, cerebrovascular accident; BUN, blood urea nitrogen.
received antihypertensive therapy. After only 3 years, control
of blood pressure was shown to afford unmistakable protection
against hypertension-induced cardiovascular complications.
Strikingly, antihypertensive treatment reduced by 75% the
morbid effects of untreated moderate hypertension. The mantle
of chemotherapeutic protection was now acceptably extended
to cover hypertensive patients whose DBPs were 105 mm Hg or
greater.
Still, however, the value of pharmacotherapy remained un-
tested in fully 70% of all hypertensive s—those with DBPs of 90
to 104 mm Hg—that is, approximately 40 million people in the
United States alone. Indeed, the merits of such therapy have
been questioned repeatedly. Many argue from anecdotal experi-
ence that because target-organ damage infrequently compli-
cates mild hypertension, drug toxicity easily could outweigh
any minor benefit that might accrue from reducing this "trivial
increase" in blood pressure. The aforementioned studies [10—
14] suggest that the milder the hypertension, the longer it takes
for end-organ damage to appear, and the less widespread is the
tissue damage. To acquire meaningful data, therefore, trials
evaluating the drug therapy of mild hypertension must be long-
term and include large numbers of subjects in contrast to the
small number of patients studied in the early VA studies [13,
14].
We now come to the two key questions concerning us today.
(1) Is mild hypertension associated with increased morbidity
and mortality? (2) Can the putative dangers accompanying mild
hypertension be neutralized by currently available therapies?
Conceivably, a small sustained increase in blood pressure could
coexist with, but not cause, a progressive vasculopathy that
leads to morbidity and early death. In this case, mild hyperten-
sion would merely be an epiphenomenon, the treatment of
which need not result in any salutary effect on morbidity or
mortality.
The dangers of mild hypertension
Survival studies of one million 45-year-old men followed for
20 years after an initial life-insurance examination indicated that
mild hypertension was associated with early mortality [15].
Figure 2 illustrates the striking increase in death rate as the
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initial blood pressure increased. Although not demonstrating
causality, this study does strongly suggest that mild hyperten-
sion is accompanied by an increased risk of early death. A
review of 5 studies in which individuals with untreated border-
line hypertension were followed for 10 to 20 years confirmed
the aforementioned risk [161. Borderline hypertension is de-
fined as the intermittent presence of mild hypertension. The
excess early mortality in the affected group—as compared with
normotensive controls—largely was accounted for by cardio-
vascular complications and primarily was restricted to those
who developed sustained hypertension [16].
The Framingham population studies demonstrated that the
death rate increased dramatically and progressively as the DBP
increased above 90 mm Hg [17]. Figure 3 integrates these data
with the distribution in blood pressure found when almost
160,000 people were screened during the Hypertension Detec-
tion and Follow-Up Program (HDFP) [181. Synthesis of these
two studies suggests that almost 60% of the excess deaths
associated with hypertension occur in those with DBPs ranging
from 90 to 104 mm Hg (Fig. 3). The danger to a given individual
with mild hypertension is small because the risk of complica-
tions varies directly with the increase in the blood pressure.
Although the percentage of patients with mild hypertension
manifesting end-organ damage is undoubtedly far less than that
in those with severe hypertension, the enormous size of the
former population makes that group responsible for the greatest
absolute number of deaths.
Evidence that treatment of mild hypertension reduces
morbidity and mortality
What follows is a brief, critical review of the 5 studies most
frequently cited in evaluating the effects of drug therapy on mild
hypertension (Table 2). Note that only two studies, the HDFP
0
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Fig. 3. Excess death rate caused by diastolic blood pressure greater
than 90 mm Hg. Top panel illustrates death rate found in Framingham
studies; middle panel depicts distribution of blood pressures found in
screening almost 160,000 people during HDFP; bottom panel: inter-
grates the above two and defines the percentage of excess death
according to the degree of hypertension. (Reproduced with permission
from Apostilides et al [18].)
and the Australian, investigated the large number of patients
that many believed were needed to evaluate the treatment of
this relatively mild disorder. The relatively small number of
subjects included in the VA [14], United States Public Health
Service (USPHS) [19] and Oslo [201 studies renders interpreta-
tion of their results problematic. Only the VA and the USPHS
studies utilized a double-blind, randomized, placebo-controlled
design; only the HDFP included adequate numbers of males
and females, and the racial distribution of the studies varied.
VA Cooperative Study. Acceptance for inclusion in the VA
trial required that the DBP remain greater than or equal to 90
mm Hg after 6 days of evaluation in the hospital. By excluding
those whose DBP fell below 90 mm Hg, the study probably
selected a more severely affected subgroup from the total
population of mild hypertensives. During a prerandomization
placebo period, 170 patients demonstrated their ability to
comply with the drug regimen; 86 were randomly accepted into
the treatment group and 84 into the placebo group. Therapy
included hydrochlorothiazide, reserpine, and hydralazine, ad-
ministered in stepwise fashion. After approximately 3 years, 21
morbid events accrued in the placebo group, but only 14 such
occurrences developed in the treated group [14]. This 35%
reduction in morbidity was less than the 75% reduction found in
the drug-treated group with DBP of 105 to 114 mm Hg. The
reduction in hypertensive complications in this small, short-
term study largely was restricted to men older than 50 years and
to patients manifesting end-organ involvement on admission.
Some clinicians narrowly interpret these results as suggesting
that men with DBPs between 90 and 104 mm Hg do not require
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Fig. 2. Effect of entry blood pressure (recorded in bar graphs at left) of
men at age 45 years on their death rate over the ensuing 20 years.
(Modified from [151.)
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Table 2. Therapy of mild hypertension: Characteristics of the major studies
Study
No. of
patients
Entry DBP
(mm Hg) Study design Sex Age Race
VA Coop [14] 210 105—114 Randomized, double-blind,
placebo controlled
M 49b 42%
B
170 90—104 M
USPHS [191 389 90—114 Same 80%
M
21—55 72%
W
HDFP [21—24]
Total 10,940 90—115 Open, randomized trial: stepped
care vs. referred care
54%
M
50.8" 45%
B
Stratum I 7,825 90—104
Australian [29—30] 3,427 95—109 Single-blind, placebo controlled 63%
M
30—69 W
Oslo [20] 785 110 Open, randomized, no placebo M 40—49 W
a Abbreviations: DBP, diastolic blood pressure; VA Coop, Veterans Administration Cooperative Study Group on Antihypertensive Agents;
USPHS, United States Public Health Service study; HDFP, Hypertension Detection and Follow-up Program; B, black; W, white.
b Mean age.
therapy until middle-age or until target-organ damage has
developed. Others question the value of withholding therapy
until potentially irreversible damage has occurred. It is also
important to emphasize that 24 of the 184 subjects (13%) taking
placebo developed a sustained DBP of 124 mm Hg or acceler-
ated hypertension.
United States Public Health Service (USPHS) Study. Like
the VA Cooperative Study, the USPHS trial utilized a double-
blind, randomized, placebo-controlled protocol but involved
only 389 subjects, a relatively small number [19]. The popula-
tion studied was younger than that investigated in the VA trials,
21 to 55 years, and unlike the VA study, subjects with end-
organ damage were excluded. The USPHS trial lasted 7 to 10
years. A combination tablet containing chlorothiazide (500 mg)
and rauwolfia (100 mg), taken twice daily, reduced the BP by
16/10 mm Hg in the treated group; no significant change was
observed in those receiving placebo. Ominously, 33 subjects in
the placebo group (17%) developed DBPs of 130 mm Hg on 3
separate occasions or manifested advancing retinopathy. Anti-
hypertensive therapy reduced the total number of first morbid
events (those specifically related to hypertension plus those
more clearly related to atherosclerosis) by 38% (Table 3). This
improvement, however, was entirely limited to the hyperten-
sive complications; the atherosclerotic changes developed with
equal frequency in both groups. The benefit of therapy largely
was manifested by the prevention of electrocardiographic and
roentgenographic signs of hypertensive heart disease. Failure of
antihypertensive agents to prevent the effects of atherosclerosis
has been ascribed to the selection of a young population, free
from overt end-organ disease and studied for a relatively short
period.
Hypertension Detection and Follow-up Program (HDFP).
Although a large study evaluating the effects of hypertensive
therapy was still needed, the benefits demonstrated by previous
VA trials were considered so clearcut that it was deemed
unethical for new studies to include a placebo group. To
circumvent this issue, the HDFP compared therapeutic benefits
of pharmacotherapy in a vigorously treated group—the
stepped-care group (SC)—with a matched, but less aggressively
treated, group—the referred care group (RC) [21—24]. Almost
160,000 subjects were screened; 10,940 people with varying
degrees of hypertension, with or without manifest target-organ
damage, were randomized into SC and RC groups and followed
for 5 years. The SC group received free medical care and
transportation to 14 specialized centers where they were seen
as frequently as needed but at least once every 4 months. A
committed clinical staff vigorously attended to their care and
urged compliance with therapy. Waiting times, appointment
hours, and the availability of physicians all were arranged to
enhance compliance. Stepped care was initiated, with a diuret-
ic, potassium supplements, or potassium-sparing agents being
added as deemed necessary. Reserpine or methyldopa was
added as a second step, hydralazine was included as a third
step, and finally, guanethidine was given as a fourth step. The
therapeutic goal was to sustain a DBP at 90 mm Hg or, for those
with initial pressures between 90 and 99 mm Hg, to obtain a
reduction of 10 mm Hg. Thus, the final DBP approached 80 mm
Hg in many subjects. The RC patients were returned to their
private physicians for whatever form and intensity of treatment
was considered appropriate. It was anticipated that antihyper-
tensive therapy would be much less vigorous in the RC group.
In addition to their assigned mode of care, all RC and SC
subjects were questioned and examined at home once yearly
during study years 1, 2, 4, and 5.
Because most patients in the RC group were also receiving
medication, any benefit of the more aggressive antihypertensive
therapy in the SC group would be less evident. Thus, any
demonstrated reduction in morbidity and mortality rates in the
SC subjects in this study would be all the more impressive.
Subjects in both groups were divided into 3 strata according
to their DBP: stratum 1, 90 to 104 mm Hg; stratum II, 105 to 114
mm Hg; and stratum III, 115 or higher mm Hg. I will review
only the results from stratum I, the mild hypertensive patients.
This stratum accounted for 71.5% of the total population, that
is, 7825 subjects; 3903 were randomized to SC and 3922 to the
RC subgroups. Death was chosen as the primary end-point for
this study; the cause of death was obtained from death
certificates.
At years 1, 2, 4, and 5 the percentage of RC subjects
achieving their goal DBP (i.e.,  90 mm Hg or a reduction of 10
mm Hg for those with an initial DBP of 90 to 99 mm Hg) was
30.4, 34.9, 40.7, and 43.0 as compared with 51.9, 57.2, 61.6, and
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Table 3. USPHS 10-year study: The effect of antihypertensive therapy on first morbid events (DBP 90-114 mm Hg)
Complications
Active (193 subjects) Placebo (196 subjects)
N % N %
Total first morbid events 56 29 90 46
Hypertensive (total) 29 15 65 33
CVAb 0 — 2 0.5
LVH 9 4.7 23 12.2
LVSbyECG 10 5.2 22 11.2
Cardiomegaly 10 5.2 15 7.7
Retinopathy 0 — 3 1.5
Atherosclerotic (total) 27 14 25 13
MI 7 3.6 6 3.1
Death 1 0.5 1 0.5
Other CHD 18 9.3 18 9.2
CVD-TIA 0 — 0 —
Arterial insufficiency 1 0.5 0 —
Data from Circ Res 40 (suppl 1)1-98, 1977
Abbreviations: CVA, cerebrovascular accident; LVH, left ventricular hypertrophy; LVS, left ventricular strain; ECG, electrocardiogram; MI,
myocardial infarction; CHD, coronary heart disease; CVD, cerebrovascular disease; TIA, transient ischemic attack.
63.8 for the SC group [22]. Mean DBP on entry was the same in
the RC and sc groups. The mean DBP for study years 1, 2, 4,
and 5 for the RC subjects was 91.9, 90.7, 88.4, and 87.8 mm Hg
[22]. Respective values for the sc group were 86.4, 85.7, 83.8,
and 83.4 mm Hg [22]. Thus, although significant decrements
were achieved in the RC group, the DBP was reduced more
consistently and to a greater extent in the SC subjects.
The 5-year death rate was significantly reduced in the SC
participants. This improvement was demonstrated in the entire
group and in each of the substrata (Table 4). The surprisingly
high mortality rate, 5.9% to 7.4% over 5 years, has been
attributed to the inclusion of subjects with end-organ pathology.
The mortality from cardiovascular diseases included 31 deaths
from cerebrovascular disease and 56 deaths from myocardial
infarction in the RC group, whereas the SC subjects suffered
only 17 cerebrovascular fatalities and 30 lethal heart attacks
[221. This dramatic reduction in deaths from cerebrovascular
disease is entirely in accord with the findings in the other 4
major studies. The 46% reduction in fatal myocardial infarc-
tions, however, is a unique observation vis-à-vis the other
studies. This may be a function of the large number of subjects
included in the HDFP. Based upon serial responses to the Rose
Questionnaire—designed to evaluate subjects for myocardial
infarction and angina pectoris—the SC group had a 15.2% lower
incidence of angina pectoris than did the RC group (P < 0.05)
[25]. Although the trend suggested that myocardial infarctions
occurred less frequently in the SC group, the numbers did not
attain statistical significance [25].
A 14% improvement in the non-cardiovascular mortality rate
also was realized by the SC group during the 5 years of study.
This observation has led many to question whether the im-
proved mortality enjoyed by SC subjects was more a function of
their better and more intense general medical care rather than
only control of their hypertension. Advice as to diet, smoking
habits, and weight control was probably more vigorously pre-
sented to the SC group than to the RC subjects. The HDFP
investigators point persuasively to 3 observations that tend to
negate this interpretation. First, no differences were observed
between SC and RC groups in serum cholesterol concentration,
smoking habits, or weight control [26]. Better general medical
Table 4. HDFP 5-year death rate for stratum I (DBP 90—1 04 mmHg)a
Difference in
Entry
DBP
Death
--
Stepped
ate (%)
Referred
mortality
RC-SC (%)
RC-SC
(mm Hg) care care (%) RC
Total stratum 90—104 5.9 7.4 1.5 20.3b
Substrata 90—94
95—99
100—104
5.7
5.0
7.5
7.3
6.5
8.7
1.6 21.9"
1.5 23.1"
1.2 13.8"
a Table modified from Ref. 24.
b P < 0.01.
care would have been expected to alter these parameters
favorably. Second, a statistically significant increase in the
progression of tall R waves to definite left-ventricular hypertro-
phy (LVH) was seen in the RC group (P < 0.05) [27]. Converse-
ly, normalization of tall R waves and regression of definite LVH
found on entry into the study was more common in the SC
group, as was their loss of x-ray evidence for cardiomegaly [27].
These changes would not be expected to accrue simply from
improved general medical care, but would be anticipated from
effective treatment of hypertension. Finally, Hardy and Haw-
kins have shown that during each year of the study, survivors
had significantly lower blood pressures than did those who died
[281. By use of the statistical technique of life-table regression
with time-dependent covariants, these authors demonstrated
that the bulk of reduction in mortality in the SC group was due
to control of blood pressure [28]. On balance, therefore, these
data strongly suggest, but do not prove, that SC subjects
benefited primarily from successfully treated hypertension.
Approximately 25% of SC and RC subjects in stratum I were
taking antihypertensive agents when entered into the study.
One might surmise therefore that if the drugs had been discon-
tinued, the DBPs might have exceeded 104mm Hg. If true, this
"loading" of stratum I with more severely hypertensive pa-
tients would worsen the prognosis of the RC subjects and
improve that of the SC group. It has been claimed, however,
that the SC subjects manifested the same improvement when
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Table 5. Australian Therapeutic Trial in Mild Hypertensiona
Result Placebo (n = 1706) Drug (n = 1721) Therapeutic improvement(%)
Mortality
Total 19 9 53
Cardiovascular 13 4 69
Noncardiovascular 6 5 17
Trial end-points 127 91 28
Cerebrovascular events
Total 25 12 52
Fatalities 4 2 50
Nonfatal hemorrhage
or thrombosis 13 7 46
TIA 8 3 63
Ischemic heart disease
Total 88 70 20
Data from Ref. 29.
the calculations were made after deleting from both groups
those previously treated [41.
The improvement in SC morbidity was least apparent in
white women and in individuals under 50 years on entry. White
women in the RC group apparently were treated more frequent-
ly than other members of this group, and this deviation in the
protocol thereby blurred the difference in their mortality rate
with that of their counterparts in the SC group.
The HDFP study group has concluded that a sustained and
substantial reduction of blood pressure can be achieved with
the SC approach and that such reduction in patients with mild
hypertension protects against cardiovascular death and signifi-
cantly prolongs life.
Australian Therapeutic Trial in Mild Hypertension. After
careful screening, 3427 subjects aged 30 to 69 years (mean 50.5)
with DBPs ranging from 95 to 109 mm Hg were randomly
assigned to placebo or drug treatment groups [29, 301. These
patients were free of end-organ pathology (except for LVH). A
certain bias in the intensity of follow-up care of the placebo
group might have been permitted to intrude, because the
participating physicians knew which subjects were receiving
antihypertensive agents and which were receiving placebo.
Diuretics were used as first-step therapy, followed by either an
adrenergic beta-blocking agent or alpha-methyldopa as the
second step, and hydralazine or clonidine as the third-step
agent.
After an average follow-up period of 4 years, distinct benefits
of therapy became manifest (Table 5). Therapy reduced by
almost 30% (P < 0.01) the renal, cardiac, cerebral, and other
trial end-points, and the total mortality rate was diminished by
53% (P < 0.05). The improvement in cerebrovascular complica-
tions was most striking (Table 5), whereas the improvement in
ischemic heart disease did not quite achieve statistical signifi-
cance (P = 0.051). As with the HDFP, white women and patients
less than 50 years old manifested little benefit from therapy.
In addition to the salutary effect of drug therapy, the sponta-
neous blood pressure changes noted in the placebo group were
of great interest. Twelve percent, or 202 of the 1706 subjects,
manifested a sustained increase in DBP to values in excess of
110 mm Hg, whereas DBP fell to values below 95 mm Hg in
fully 48%! This spontaneous decrement in DBP dramatically
underscores the need for documentation of the sustained nature
of mild hypertension before therapy is begun.
Table 6. The 5 therapeutic trials of mild hypertension. Cumulative
complications in control and treated groupsa
Complications
Control
N' %
Treated
Nb %
% Improvement
Control-treated
Control
Total morbid events 563 9.0 417 6.6 27
Total mortality 342 5.4 262 4.1 24
Cerebrovascular events:
Fatal and nonfatal 140 2.2 76 1.2 50
Fatal coronary events 79 1.2 46 0.7 42
a Data culled from the VA Coop. Study: DBP 90—104 [14]; USPHS
Study [191; HDFP: Stratum I [21—24]; Australian study [29, 30]; Oslo
study [201.b Total control and treated populations are each approximately 6400
subjects.
The Oslo study. This study randomly allocated 785 subjects
with systolic blood pressures of 150 to 179 mm Hg and DBPs
less than 110 mm Hg to drug therapy (406 subjects) and control
groups (379 subjects) [20]. The latter were untreated but did not
receive placebo. Thus, this "open" study allowed physicians
and patients knowledge of who was receiving active treatment.
Only white men 40 to 49 years old and without end-organ
pathology were entered and followed for an average of 66
months. No differences in overall morbidity or in cardiovascu-
lar morbidity were noted between the groups; however, 7
control subjects suffered cerebrovascular accidents whereas
none of the treated group did. A statistically insignificant
increase in coronary artery disease (20 events) was noted in
drug-treated patients as compared with controls (13 events). In
17% of the control group, systolic and diastolic blood pressures
exceeded 180 and 110 mm Hg, respectively. Evaluation of this
trial is made difficult by its open design and by its selection for
study of a relatively young, low-risk population.
Summary of the observations: The cumulative complications
in control and treated groups in the 5 trials
Mortality and morbidity data have been culled from the five
trials, and the control and treated groups have been compared
(Table 6). Total morbidity figures include data from the VA
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study, in which DBPs ranged between 90 and 104 mm Hg [14],
and data from the HDFP, which were mortality statistics from
stratum-I subjects [21—24]. Subjects from the VA study, with
DBPs ranging from 90 to 114 mm Hg, were used in evaluating
the effects of therapy on mortality and on the development of
cerebrovascular and coronary events. The cumulative data are,
of course, markedly influenced by the large numbers contribut-
ed by the HDFP (7800 subjects) and Australian studies (3400
subjects).
All 5 studies demonstrated that the antihypertensive therapy
reduced morbidity as well as decreased the incidence of fatal
and nonfatal cerebrovascular events. Mortality rates were
lowered by drug therapy in the large population studies. The
low mortality reported by the USPHS and Oslo studies is
attributable to the small groups evaluated and to the relatively
young age of the participants. Only the HDFP study showed a
statistically significant reduction in mortality from coronary
artery disease. Similar trends were seen in the smaller VA and
Australian studies. Only four fatal myocardial infarctions oc-
curred in the USPHS study; inexplicably, in the Oslo study, six
heart attacks affected the drug-treated group, whereas only two
occurred in control subjects.
Drug side effects. Prospective, well-designed protocols as-
sessing this most important aspect of hypertensive therapy are
very scarce. Toxicity severe enough to warrant discontinuation
of one or more antihypertensive agents developed in 1.4% and
in 1.1% of VA patients followed for 2 to 3 years with DBPs
greater than 115 mm Hg and 90 to 114 mm Hg, respectively.
Reserpine-associated depression and ulcers accounted for most
of the observed side effects. During the 7- to 10-year course of
the USPHS study, only 9.8% of treated subjects had to discon-
tinue taking their medication. Note that 2% of the placebo
group also had to abandon "drug" therapy because of per-
ceived untoward reactions. During the Oslo study, 41% taking
alpha-methyldopa were switched to propranolol because of
drowsiness. Repeated questionnaires and interviews through-
out the 5-year HDFP trial revealed that 15.1% of the stratum-I
subjects, 394 patients, had definite or probable adverse drug
reactions [31]. The vast majority of these were mild dermatolog-
ic, neuromuscular, psychiatric, or gastrointestinal distur-
bances, typically requiring only that administration of the drug
be discontinued. Indeed, over the 5 years, only 28 of the 5485
subjects in all 3 SC strata required hospitalization for drug
toxicity [311. No drug-related deaths were noted. Inclusion of
"possible" drug reactions brings to 36.3% the incidence of
untoward effects found over 5 years of intensive SC therapy. A
similar rate of adverse drug reaction was recorded by the
British Medical Research council Working Party on Mild to
Moderate Hypertension [32]. Criteria employed for defining
drug reactions were similar to those of the HDFP. Data from
these relatively short-term studies suggest that drug reactions,
although fairly common, generally are rather mild. Given our
ever-expanding armamentarium of effective antihypertensive
agents, I believe that drug toxicity need not be a major
impediment to the pharmacologic therapy of mild hypertension.
Unrecognized but cumulative toxicity of drugs taken on a daily
basis for decades is of real concern and demands constant vigil.
Recent extensive and critical reviews of the putative hyperlipi-
demic effects of diuretics suggest that if any lipidopathy is
induced, it is likely to be of trivial magnitude and has not been
shown to be sustained [33; Brest A, personal communication].
The rush to condemn diuretics on the basis of several 4- to 12-
week studies demonstrating an associated mild hyperlipidemia
seems ill advised at this time. One should await publication of
carefully controlled, prospective, long-term studies.
Recommendations. The evidence that mild hypertension is
associated with early death and morbidity from cardiovascular
disease is, in my opinion, most strongly suggested by the
population studies reviewed here [15—18]. All studies have
consistently demonstrated that lowering of even mild degrees of
hypertension affords protection from complications such as
fatal and nonfatal stroke and ventricular hypertrophy. The
evidence that the development and progression of coronary
artery disease diminishes when high blood pressure is reduced
is strongly suggested by the largest therapeutic trial (HDFP);
the other studies were equivocal on this point (Table 6). The
Framingham study, however, indicated that hypertension is but
one of many risk factors predisposing to coronary artery
disease [17]. Thus, reduction of blood pressure without simulta-
neously improving lipid metabolism, obesity, cigarette smok-
ing, and the myriad known and currently unknown factors
malevolently affecting the coronary arteries is not likely to yield
crisp, clear-cut results. Although the benefit of reduced blood
pressure on coronary atherosclerosis has not been clearly
proved, the trend is apparent.
For these reasons, most clinicians agree that even mild
hypertension ought to be treated, but debate rages as to the best
way to effect this therapeutic change [1, 21. Some take the view
that the minimal risk of mild hypertension to the individual is
outweighed by a greater risk of drug toxicity accruing from a
lifetime of pharmacotherapy. Nonpharmacologic therapy is
advocated by this group. Ram has argued against routine
chemotherapy of mild hypertension on the following grounds.
Stepped-care therapy reduced the mortality by 1.5% as com-
pared with referred care subjects in stratum I. Thus, for every
100 mild hypertensives receiving stepped care, fewer than 2
benefit, and 98 are needlessly treated [81. Other authors are
quick to note, however, that if the HDFP had been extended
beyond 5 years, the percent reduction in mortality might have
been greater. Since hypertension is a life-long disease, and
because subjects develop complications at variable rates, the
longer the study the greater the likelihood of increasing bene-
fits. Second, the study's reliance only on mortality as an end
point obviated recognizing any effects of therapy on nonfatal
morbid events. Prevention of all complications, not just the
lethal ones, should impressively expand drug benefit. It is also
likely that, with more sophisticated use of newly developed and
standard antihypertensive agents, the risks and cost/benefit
ratio of our therapy will continue to decline.
Several forms of nonpharmacologic treatment—diet therapy
and relaxation therapy—have been shown by short-term, often
uncontrolled studies, to variably lower blood pressure [1].
Whether weight reduction, independent of salt intake, and then
modest sodium restriction per se can sustain the demonstrated
short-term hypotensive effects remains to be shown [34, 351.
Alcohol excess can increase blood pressure [361; therefore it
should be avoided. Suggestions that hypertension is improved
when the diet is supplemented with potassium and calcium
require careful confirmation [37, 38]. Invocation of biofeedback
techniques, Eastern meditative methods of relaxation, and
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isotonic exercise may prove helpful for some hypertensive
patients [391
In my experience, many patients seem to have great difficulty
even remembering to take several pills each day. How then can
they be expected to reliably render repeated daily incantations
to the gods of relaxation and hypotension? Most physicians can
easily identify the subpopulation of hypertensives likely to
accept such therapies. All patients should be made aware of the
virtues of a wholesome diet, relaxation, maintenance of their
ideal weight, and abstinence from alcohol. For years many of us
have espoused these chaste ideals with something less than
overwhelming success. Finally, how many patients with mild
hypertension will consider trivial a disease "not severe enough
to warrant medical therapy?" This important question needs
clarification.
Where, then, does pharmacologic therapy stand as an option
for patients with mild hypertension? One must be impressed by
the Australian observation that the DBP, initially ranging
between 95 and 110 mm Hg, spontaneously fell to values below
95 mm Hg in almost 50% of their control subjects [29, 30].
Therefore, it seems most appropriate to follow the recent World
Health Organization recommendation that mild hypertension
ought not be diagnosed unless a DBP greater than 90 mm Hg is
documented on at least 3 separate occasions spanning a period
of 4 weeks 140]. Conversely, 12% to 17% of subjects with mild
hypertension escalate their pressures into higher, more clearly
dangerous strata, making it foolhardy for anyone to minimize
the importance of an initial DBP between 90 and 99 mm Hg.
An estimated $20 billion would be required annually to
provide drugs and ancillary care for this country's approximate-
ly 40 million patients with mild hypertension [3]. Add to these
costs the expense and discomfort of drug toxicities, and the
costs continue to soar. As questioned by Dr. Frohlich, howev-
er, what gains do we achieve in dollars and cents by preventing
stroke, congestive heart failure, and myocardial infarction [2]?
Reduced numbers of hospital and nursing home admissions and
the sustained productivity of tax-paying, viable patients with
hypertension certainly translate into savings that could offset
the estimated expenses. Until these figures become clarified,
until nonpharmacologic therapy is widely accepted by patients
and shown to provide sustained normotension, and until newer
data supersede the summarized therapeutic trials, I would
recommend pharmacologic therapy for anyone with a persistent
DBP of 90 mm Hg or more. This recommendation is especially
important for individuals manifesting additional risk factors
such as hypercholesterolemia, diabetes mellitus, obesity, a
family history of hypertension, and the presence of end-organ
damage.
Questions and answers
DR. JEROME P. KASSIRER: Dr. Narins, most of the studies
you reviewed today focus on the benefits of therapy, typically
measured by reductions in morbidity and mortality, that are
achievable by treatment of mild hypertension. What is often
neglected in these studies are the "costs" of such therapy.
Indeed, any reduction in the quality of a patient's life that
results from dietary alterations, exercise programs, drug side
effects, or other interventions must be weighed against any
benefits achieved by treatment. If an analysis of this complex
tradeoff could be carried out, I suspect, as Pauker and I
proposed (41), that the choice to treat or not to treat would be a
close call, that is, that there is little difference in overall
outcome between treating and not treating.
DR. NARINS: When viewed in terms of the population at risk,
appropriate lowering of even mildly elevated blood pressure
reduces eventual hypertensive end-organ damage and probably
diminishes the incidence of atherosclerotic cardiovascular dis-
ease [21]. The relatively short-term studies of mild hypertension
reviewed today suggest that the small percentage of this large
population that eventually manifests the consequences of hy-
pertension translates into little risk to a given subject but
spawns a large absolute number of morbid events and fatalities.
Thus, physicians and patients must weigh the objective risks,
expense and less easily measured subjective discomforts of
treatment against the potential dangers of untreated mild
hypertension.
Although not meticulously assessed in terms of subjective
responses, the HDFP study does suggest that drug-induced
major morbidity and mortality were quite rare in treated hyper-
tensives [31]. Annoying side effects were common, but given
our ever-expanding pharmacologic armamentarium, most sub-
jects can be provided with the right dose of the right drug so as
to minimize sustained untoward reactions.
Opponents of drug therapy stress the dangers of side effects
but often forget that recommended therapeutic alterations in
diet and exercise provoke changes in lifestyle that may not be
acceptable to many mild hypertensives. Lack of compliance,
guilt, or outright hostility are often manifested by those incapa-
ble of accepting these oftentimes demanding programs. The
balance between the long-term benefits of controlled mild
hypertension and the dangers and discomforts from the compli-
cations of pharmacologic and non-pharmacologic therapy has
yet to be clearly defined.
My reading of the literature suggests that the benefits of
combined pharmacologic, dietary, and exercise therapy of mild
hypertension outweigh measurable costs. I recognize, however,
that a given hypertensive's subjective response to our suggest-
ed treatments is quite variable. The risks of partial or no
treatment should be carefully explained to those resisting
therapy. Those electing not to accept a recommended program
should be strongly encouraged to have their blood pressures
routinely evaluated and should their hypertension worsen,
therapy must be initiated.
Finally, I fully agree with your inference that only with
meticulous testing of both objective and subjective responses to
therapy can we get at the "total cost" of treating mild hyperten-
sion. Currently, our information on this important point is quite
limited.
Da. NIcoLAos E. MADLAS: Approximately 15% of patients
with borderline hypertension develop sustained hypertension
over a 10-year period of observation and some evidence sug-
gests that the increased morbidity and mortality of the border-
line hypertensive population as a whole might mostly emerge
from the segment that goes on to develop sustained hyperten-
sion. Despite the zeal and organized practices of the HDFP
personnel, it is interesting to note that by year 5, only 65% of
the stepped-care patients had achieved goal blood pressure, as
opposed to 44% of the referred-care group. Is there any
evidence to suggest that most of the morbidity and mortality
observed in the two populations of the HDFP study originated
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from those patients who did not achieve goal blood pressure?
Indeed, it would be interesting to see whether one could
correlate the morbidity and mortality risks with the level of
blood pressure achieved in the course of the trial.
DR. NARINS: If the difference in mortality between SC and
RC groups were indeed produced by the differences achieved in
blood pressure control, then intragroup as well as intergroup
mortality should also correlate with the degree of hypertension.
In other terms, within the RC and within the SC groups,
mortality ought to be higher in those not achieving goal blood
pressure than in those reaching prescribed levels of
normotension.
As previously discussed, the statistical analysis of the HDFP
results used by Hardy and Hawkins [281 enabled them to isolate
and identify the impact of blood pressure control in determining
the reduced mortality in the SC group. They showed that
control of hypertension accounted for almost two-thirds of the
improved survival manifested by SC subjects [281. This study
also asked the question: "Was there a relationship between
treatment of hypertension in the program and the risk of
subsequent mortality of the participants regardless of whether
treatment was stepped care or referred care?" While the
absence of a true placebo-control group introduces the potential
for bias and complicates the analysis, the authors conclude that
there is clearly a salutary effect of blood pressure control on
mortality regardless of whether intergroup or intragroup analy-
ses are done. Indeed, they observed ". . .that the force of
mortality is reduced by approximately 1 percent for each mm
Hg reduction in blood pressure" [281. These data apply to all
the HDFP subjects as well as to those in stratum I (DBP 90—104
mm Hg). Thus, in direct answer to your question, it appears
that it is the control of blood pressure that affords protection
regardless of whether this control was effected in the SC or RC
subjects. Moreover, within both groups, those whose pressures
were reduced had a reduced mortality.
Ms. CAROL ST0LLAR (Assistant Director for Patient Care,
Frances Stern Nutrition Center, NEMC): We now know that
we can obtain statistically significant reductions in blood pres-
sure in most persons with mild to moderate hypertension by
sodium restriction, weight reduction, or both [42]. As is rarely
noted, the key in these studies that successfully changed
patients' dietary behaviors was the use of a dietitian/nutritionist
providing individualized nutrition counseling over time. Chang-
ing lifelong dietary habits is not an easy task, but one advantage
is that there are few deleterious side effects.
DR. NARINS: It must certainly be true that patient compliance
with recommended therapy is very strongly influenced by the
zeal and commitment articulated for that treatment by the
counselor. It matters little, in my view, whether the counsel
derives from a physician, a nurse, or any other qualified
therapist, as long as the advisor commands the patient's re-
spect. The dietician/nutritionist clearly plays a key role in
convincing and sustaining patient compliance with recommend-
ed changes in salt and caloric exposure. Busy practitioners
would do well to utilize the expertise and enthusiasm of such
specialists.
As implied by Dr. Kassirer's question and comments, howev-
er, we ought to recognize that these recommended changes in
lifestyle can be painful and unacceptable to many. While the
clinical team sees the beneficial effects of diet and exercise
programs, their impact on some patients can be every bit as
damaging as many drug side effects. Quality of life is defined in
very personal terms and I would not be too critical of those mild
hypertensives choosing one form of treatment over another, or
those opting not to receive any treatment at all. Careful follow-
up studies of treated or untreated patients is, of course, critical.
DR. JOHN T. HARRINGTON: Many investigators have looked
at the problem of the patient who walks into your office
ostensibly healthy yet walks out "sick," having been labeled as
"hypertensive." That label can have detrimental effects on
patients' sense of psychic well-being and perhaps on their
insurance status as well. Do you or should you take these
factors into account when labeling someone hypertensive with
only minimal elevations of blood pressure?
DR. NARINS: You pose an interesting question the answer to
which has been hotly debated by a number of investigators.
Haynes et al, after a blood pressure screening program in a
Canadian steel factory, found an impressive increase in absen-
teeism in subjects newly labeled as "mild hypertensives" [43].
These investigators demonstrated that the mean (±SEM) num-
ber of days lost from work increased from 2.3 0.32 days
during the year prior to screening to 8.6 2.0 days during the
year following labeling and treatment of 85 subjects previously
unaware of their hypertension. Of 53 other previously unaware
subjects who were labeled but remained untreated, absenteeism
increased similarly from 3.3 1.5 days to 8.1 2.6 days [43].
Since treated and untreated groups had comparable increments
in their disability days following screening, work loss is not
likely to have resulted from drug side effects. The authors
concluded that the increased loss of work days was best
correlated with the subjects becoming aware of their hyperten-
sion and the lack of their compliance with subsequent therapy.
These results are consistent with the Harris Poll community
survey of hypertension which revealed a twofold greater degree
of absenteeism in hypertensive subjects as compared with non-
hypertensive matched controls [44].
In contrast to these results, however, are the beneficial
results of hypertension detection and therapy reported by
Alderman and Davis [45] and by Mann [46]. The former authors
reported a decrease in the number of disability days in workers
treated for newly discovered hypertension and the latter inves-
tigator noted a reduction in psychiatric infirmity following
labeling and treatment. The HDFP results have recently been
reviewed to define changes in absenteeism occurring after the
screening and labeling of more than 10,000 hypertensives [47].
Of 1,842 subjects previously unaware of their hypertension and
entered into the SC group, no change in disability days occurred
during follow-up, whereas 1,805 similar subjects entering the
RC group manifested a significant increase of 2.3 disability days
in the year following screening. Of great additional interest is
the fact that a mean reduction of 5.7 disability days was
observed in the 1,353 previously aware and treated hyperten-
sives who were randomized into the SC group. The intense care
provided to the SC group appears to have negated development
of absenteeism and may indeed have reduced it.
Thus, the impact and psychosocial effects of labeling and
treating hypertensives are not uniform. Once again, the large
numbers and diverse population, drawn from 14 separate com-
munities across the United States by the HDFP, enhance the
credibility of its results. The much smaller numbers and more
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homogeneous population (Canadian factory workers) studied
by Haynes et al 1431 may underly the differences in results
between this study and the HDFP.
As indicated in my previous discussion, I believe that a
reasonable diet and exercise program coupled with chemothera-
py neutralizes the long-term damage from mild hypertension
and I convey this to my patients. Putting their "disease" into
proper perspective and conveying a strong sense of optimism
regarding the effects of treatment may well prevent hyperten-
sives from developing a self-defeating, negative view of their
future. I suppose that the psychosocial make-up of the popula-
tion under study will also influence the reaction to their
"disease." One could imagine that after discovery of their
hypertension, hard-driving executive, type-A personalities
would be less likely to avoid work than would more passive,
phlegmatic type-Bs.
Since many mild hypertensives eventually graduate into more
omnious hypertensive strata and since I, like many others,
believe that therapy then is indicated, I would not avoid
informing subjects about their elevated blood pressure. As with
any treatable disorder, patients must be informed and educated
by an empathic physician who is careful not to create despair
but rather an appropriate optimism for their prognosis.
It is also important to reiterate that a single elevated blood
pressure recording does not constitute evidence of hyperten-
sion. Indeed, the W.H.O. recommends that three elevated
blood pressures, spanning four weeks of evaluation, are re-
quired before accepting this label [40].
DR. ARNON DREYFUSS (Resident, Dept. of Internal Medi-
cine, NEMC): It appears that some 20% of patients with mild
hypertension progress to more severe blood pressure. Is thera-
py beneficial only in this subpopulation of patients?
DR. NARINS: Certainly those mild hypertensives suffering
further sustained elevations of blood pressure manifest greater
mortality and end-organ damage. Both the Australian and
HDFP studies, however, demonstrated increased morbidity
and mortality in those with sustained mild hypertension and
that antihypertensive therapy was protective [24, 29]. Further-
more, the HDFP study showed that SC subjects derived benefit
regardless of whether end-organ damage was already present at
the time of study [24]. These observations strongly support
early therapy, initiated prior to development of end-organ
damage.
Forum commentaries
DR. NORMAN M. KAPLAN (Professor of Internal Medicine,
Southwestern Medical School, The University of Texas Health
Science Center at Dallas, Dallas, Texas): Dr. Narins has
presented a strong and, in general, well-documented argument
in support of his recommendation of "pharmacologic therapy
for anyone with a persistent DBP of 90 mm Hg or more."
However, I think this view is too extreme, not supported by the
evidence that is currently available, and hazardous, in that it
might expose millions of people, such as the 40-year-old man
whose case introduces this discussion, to unnecessary risks.
Let me take exception to some of Dr. Narins' points and then
come back to the case, which clearly poses the therapeutic
dilemma we now face. Dr. Narins first addresses the dangers of
mild hypertension. Both the 1959 actuarial data and the 1979
data now available [48] document his argument that, overall,
even minimally elevated pressures increase the likelihood of
premature cardiovascular disease. As the Pooling Project data
show, men age 40 to 60 years with diastolic pressures between
80 and 87 mm Hg had a 52% increase in their relative risk for
coronary events over 8.6 years [491. But such data—and Figure
3 in Dr. Narins' paper is another good example—tend to
overstate the argument. The 52% increase in relative risk shown
in the Pooling Project translates to a difference in the absolute
rates of major coronary events between 6.6% in those with
DBPs below 80 mm Hg versus 10.1% in those with DBPs
between 80 and 87 mm Hg. The 3.5% difference (between 6.6%
and 10.1%), although 52% higher in relative terms, is a far less
impressive figure, but it more correctly tells the clinician an
important fact: that 3 to 4 more men of 100 men aged 40 to 60
will have a coronary event in the next 8.6 years if their diastolic
blood pressures exceed 80 mm Hg than if their DBPs had been
below 80 mm Hg. Similarly, the 58.4% of excess deaths
attributable to diastolic pressures between 90 and 105 mm Hg,
as shown in Figure 3, should not be mistakenly interpreted to
indicate that anywhere near that percentage of mild hyperten-
sives will die prematurely as a result of their hypertension. I
agree with Dr. Narins' statement, "The danger to a given
individual with mild hypertension is probably small because the
risk of complications appears to vary directly with the height of
the blood pressure." But I would go one step further: the risks
are not shared equally by all those with any given level of blood
pressure. We have a good data base, the Framingham study, to
use for an assessment of an individual patient's risk status, and
I believe one should use these other factors in addition to the
level of the blood pressure when deciding whether to treat a
patient with mild hypertension with drugs [50].
The reason for my more conservative view is contained in the
second issue addressed by Dr. Narins, whether antihyperten-
sive agents improve the overall prognosis of mild hypertension.
He and I read the same data somewhat differently. Table 5
combines the data from 5 therapeutic trials of mild hyperten-
sion; Dr. Narins concludes that total mortality was reduced by
24% and coronary mortality by 42% in those who were treated
compared to the controls. Table 7, which I have prepared,
examines the mortality rates from stroke and coronary artery
disease. I omit the Veterans Administration and US trials from
my analysis because the 400 patients involved are too few to
provide meaningful mortality data. I include the Multiple Risk
Factor Intervention Trial study (MRFIT) [511, because it in-
volved 8012 men, mostly with mild hypertension, in a design
similar to that used in the Hypertension Detection and Follow-
Up Program trials [21]. The overall data show a clear, uniform,
therapy-induced reduction in the mortality rate from stroke.
But as to mortality from coronary artery disease, by far our
most important problem, the results are spotty at best. The
treated men in the Oslo study [20] had higher mortality rates
with therapy than did the study controls. The one-third of the
patients who entered the MRFIT trial with an abnormal electro-
cardiogram and who received more intensive therapy also had a
higher mortality rate than did the less intensively treated
subjects.
As I have discussed elsewhere [521, this higher mortality rate
from coronary artery disease, mostly sudden death, might
reflect the higher frequency of hypokalemia induced by the high
doses of diuretics that were given to 80% or more of the patients
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Table 7. Trials of drug therapy for mild hypertension: mortality rates per 1000 person-years
Trials Cerebrovascular disease Coronary artery disease
Drugs vs. placebo No Rx Rx Difference No Rx Rx Difference
Australian, 1980 [291 0.9 0.4 —56% 1.6 0.7 —56%
Oslo, 1980 [20] 1.0 0 —100% 1.0 2.7 +170%
More vs. less drugs Less More Less More
HDFP, 1979 [211 1.6 0.9 —41% 5.6 4.5 —20%
MRFIT, 1982 [511
Normal ECG Not reported 3.4 2.6 —24%
Abnormal ECG Not reported 2.9 4.9 +70%
as the first, and often the only drug, in these various trials.
Other drugs might be safer, but we currently have no proof that
they are. Therefore, I believe that drug therapy of hypertension
involves a certain risk that only has become obvious with
publication of the trials shown in Table 7. The risks of therapy
were not apparent in the trials of more severe degrees of
hypertension, because the hazards were outweighed by the
significant protection conferred by therapy in patients with
moderate to severe hypertension.
Dr. Narins and I both include the HDFP data, but he uses
only the mortality from myocardial infarction, which was
reduced from 56 in the RC group to 30 in the SC group, a 46%
reduction. But the HDFP report shows that deaths from "other
ischemic heart disease" numbered 56 in the SC group versus 51
in the RC group, a 9% increase in the mortality rate in the SC
patients, more of whom received drug therapy. Nobody has
defined the difference between "other ischemic heart disease"
and "myocardial infarction," but I assume it's all coronary
artery disease. When one combines these classifications, the
reduction is 20%, not 46%.
Dr. Narins and I both interpret the data from the Australian
trial [29, 30] as strongly supporting the value of drug therapy.
But recall that the Australian patients had diastolic levels of 95
mm Hg or higher, so that the evidence from that study might not
apply to patients with diastolic blood pressures below 95 mm
Hg, who comprise about 40% of the hypertensive population.
A more recent publication from the management committee
of the Australian trial documents the variable degree of protec-
tion provided by drug therapy, depending on certain character-
istics of the patient population [53]. The Committee found that
drug therapy afforded considerable protection to thin men of
various ages who smoked, whereas no protection was con-
ferred, and actually more complications occurred, with drug
therapy among obese men of the same ages who smoked. These
data further point to the need for taking various patient charac-
teristics into account when deciding whether to use drug
therapy in patients with mild hypertension.
All things considered, I do not believe it is possible to
discount the real and potential risks of drugs, at least as we have
used these compounds in the past to treat hypertension. There-
fore, I believe we should administer drugs to those who are
otherwise at low risk only if their diastolic blood pressures
remain above 95 mm Hg after at least 6 months of non-drug
therapy, given in an enthusiastic and sensible manner.
This brings us to the case presented at the beginning. The 40-
year-old man described has a high degree of risk, with smoking,
hypercholesterolemia, sedentary life style, and a positive family
history for premature cardiovascular disease; there seems no
question that he should be given drug therapy. Although I might
prefer another drug to hydrochiorothiazide, it does seem to be
working and, as long as the serum potassium, cholesterol, and
blood sugar remain normal, I would continue this current
regimen. This man is atypical, however. Most 40-year-old men
with mild hypertension don't have all these other risk factors.
Therefore they may safely be left off drugs while receiving
various non-drug therapies in an enthusiastic and sensible
manner.
This is my last point of contention: this patient was advised to
lose weight, exercise, and reduce his dietary sodium intake to
75 mmol per day, while being followed by his company nurse
with biweekly blood pressure readings. This approach is almost
certain to support Dr. Narins' assertion about the lack of
effectiveness of non-drug therapy as reflected in his statement
that "For years many of us have espoused these chaste ideals
with something less than overwhelming success." This patient
needs a good deal more advice, support, and follow-up in order
to lose weight, likely the most effective non-drug therapy. A
regular, graded exercise program probably would help, and he
might as well reduce the sodium in his diet to 75 to 100 mmol per
day while he reduces his caloric intake.
With all the knowledge and help he can get, this patient still
might not succeed. But most patients, if properly motivated,
will at least transiently lose 10 or more pounds. If this patient
did, he likely would lower his blood pressure by 10 mm Hg and
thereby might be able to delay or escape the need for drugs.
That potential for effective control of his hypertension without
drugs should be a strong motivation for him to make a diligent
effort, not the half-hearted one he apparently made.
Whether or not the non-drug approach lowered and kept his
blood pressure at a safe level, he still would need to follow a
more reasonable diet, one lower in calories and saturated fat, to
reduce his dangerously high cholesterol level. He still would
need to quit smoking. He still would do well to perform regular
isotonic exercise. So he still needs non-drug therapies, with or
without drugs. It's not an either/or situation. If he enthusiasti-
cally pursued the non-drug approach, he just might reduce all
his risks and eliminate the need for drugs. So Dr. Narins and I
both might end up treating such a patient with antihypertensive
drugs, he probably sooner than I. But we would also both need
to do a good deal more.
DR. MARVIN MOSER (Clinical Professor of Medicine, Yale
University School of Medicine, New Haven, Connecticut and
Senior Medical Consultant, National High Blood Pressure
Education Program): Dr. Narins has presented a powerful case
for the treatment of patients with mild hypertension prior to the
development of target-organ involvement. I strongly agree with
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his conclusions and will amplify some of his reasons for
advocating early treatment.
Numerous studies have demonstrated that target organ in-
volvement increases morbidity and mortality rates in hyperten-
sive patients and, although treatment reduces mortality even in
patients with evidence of end organ involvement, it is less
effective than n patients treated before there is evidence of
target organ disease [17, 24]. At present, it is impossible to
predict which patients with mild hypertension (defined as
diastolic blood pressures between 90 and 104 mm Hg) will
develop target organ involvement or more serious hyperten-
sion, but we do have evidence that lowering blood pressure
prevents more serious degrees of hypertension. As pointed out
by Gifford et al [54], only 6 of 2,100 patients in the major clinical
trials who received active antihypertensive therapy with diuret-
ics alone or with adrenergic-inhibiting drugs had observable
progression of their disease, whereas 258 of 2096 who received
placebo or "usual or customary care" had a significant increase
in complications. In addition, because it is not possible to detect
early the slowly progressive vascular disease that can occur
with a continuously elevated blood pressure, treatment soon
after hypertension is confirmed seems logical. But should we
treat mild hypertension at diastolic pressures of 90, 95, or 100
mm Hg, or should we only treat when a patient has other
cardiovascular risk factors (as in the patient discussed by Dr.
Narins)?
As Dr. Narins stated, the HDFP analysis concluded that
patients with diastolic blood pressures of 90 to 94 mm Hg as
well as those with pressures between 95 and 100 mm Hg, with
or without target organ involvement, benefited from blood
pressure lowering [24]. A recent paper from the Australian
Group on Mild Hypertension also documents that morbidity
and mortality, as defined by total cardiovascular complication
endpoints, were lowered in men and women with diastolic
pressures above and below 100 mm Hg; patients with diastolic
pressures below 95 mm Hg were not studied [291. Some
observers continue to report that the Australian study did not
demonstrate benefit unless diastolic pressures were 100 mm Hg
or higher, but this recent report from the Australian Manage-
ment Committee [29] should settle this issue.
The argument that only a few patients benefit from early
treatment of mild hypertension also has been advanced as a
reason to delay therapy. The HDFP data demonstrated an 8.7/
10(Y death rate in the RC (referred care) group compared to a
rate of 6.4/1000 patients in the SC (special care) group of mild
hypertensives. Assuming that there are 20 million patients with
mild hypertension in the United States, approximately 46,000
lives would be saved yearly by effective therapy based upon
these data. We can compare this to estimates of 10,000 patients
saved yearly by the considerable efforts and expenses of
coronary care units [55].
As Dr. Narins notes, we may end up treating more people
than necessary if we treat pharmacologically without a suitable
period of observation. During the observation period, we can
confirm the elevation of blood pressure and try nonpharmacolo-
gic therapy, which may be effective in 20% to 25% of cases. As
noted, the experience and data from the Australian as well as
the U.S. Public Health Service [19] and the HDFP studies tell
us that blood pressure will decrease to below 90 mm Hg without
treatment in some ptients, especially those with mild hyperten-
sion. Although the Australian study suggested that blood pres-
sure in 47% of patients on placebo decreased to below 95 mm
Hg and remained there for 3 years, this may not be the case.
Abernethy [56] noted that patients who had not complied at
three years (about one-third of the total population randomized
in the trial) and the 127 patients who developed complications
were excluded from the total sample analysis. In addition, over
200 patients whose pressures decreased below admission crite-
ria levels and who never were entered in the placebo trial also
were included in this sample. Actual placebo responders (to less
than 95 mm Hg) approached 20% to 25% of the total group; this
percentage is similar to that of other studies, but the fraction
comprises a large number of individuals considering the fre-
quency of hypertension in the population. It is reasonable
therefore to wait for about 3 to 6 months prior to instituting
therapy in mild hypertension in the hope of reducing the
number of patients who might be treated unnecessarily; indeed
this is the recommendation of the Third Joint National Commit-
tee on Detection, Evaluation and Treatment of High Blood
Pressure [57].
The argument against pharmacologic treatment of mild hy-
pertension stems from theoretical objections to treatment, in
my opinion. In all major studies where diuretic therapy was
used initially and a stepped-care program was followed, mor-
bidity and mortality have been reduced, not increased, the
MRFIT Study [51] notwithstanding.
Dr. Narins is correct—although transient elevations in cho-
lesterol and triglyceride levels do occur with diuretic and beta
blocker therapy, both the HDFP and the MRFIT studies
reported that after 1 to 2 years lipid levels returned to or
decreased below pretreatment levels in the actively treated
patients and remained there until the end of the study at 5 to 6
years [24, 51]. Short-term evaluation of lipid levels is of
doubtful significance and should not be used, in my opinion, as
an excuse to withhold specific drug therapy in hypertensive
patients at risk. Physicians treat patients with angina and
patients with previous myocardial infarctions with beta
blockers despite their effect on lipids, because studies have
shown a decrease, not an increase, in mortality in these patients
who not only obtain symptomatic relief but live longer (i.e., the
demonstrated benefit outweighs a theoretic risk) [58].
One study not reviewed by Dr. Narins is the Multiple Risk
Factor Intervention Trial (MRFIT) [51], which was not actually
a trial of the effects of antihypertensive drug therapy. The
results of this study have been widely misinterpreted and have
been used to argue against the therapy of mild hypertension,
especially with diuretics.
The MRFIT was a multiple risk factor reduction trial which
demonstrated, in my judgment, that the treatment of several
risk factors, both in a usual care setting (UC) and in specially
designed clinic centers (SI), reduces mortality from cardiovas-
cular disease. In the UC group 442 deaths had been expected
based on Framingham risk factor analysis, if risk factors were
not changed significantly over the 5- to 6-year period of the
study, and a sharp reduction in deaths had been anticipated in
the SI group. Only 260 deaths in the UC group and 265 in the SI
group actually occurred, however. Risk factors were reduced in
both groups and mortality was reduced to an equal degree. The
subgroup analysis that demonstrated a possible increase in the
mortality rate in patients in the SI group with abnormal resting
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electrocardiograms and hypertension lacks statistical power. In
addition, mortality in the UC patients with abnormal ECGs was
lower than that in UC patients with normal pretreatment ECGs.
This finding is at variance with all other studies, regardless of
treatment, and it makes analysis even more difficult.
It has been suggested that diuretic-induced hypokalemia
might have contributed to the increased mortality rate and that
perhaps patients with less severe hypertension and ECG abnor-
malities should not be treated with diuretics. However, in the
group of SI patients receiving high-dose diuretics and in whom
exercise stress tests proved abnormal, mortality was lower, not
higher, than in the UC group. It is within this group that one
would expect to find patients with ischemic heart disease who
might experience a deleterious effect from diuretic-induced
hypokalemia. We should not ignore the potential effects of
hypokalemia, especially in those patients with heart disease,
and especially those with ectopy, but the MRFIT results are
inconclusive. We recently analyzed this study carefully and
noted that the aberrancies and inconsistencies make interpreta-
tion difficult and do not mandate treatment changes [59]. If
there is a lesson from MRFIT (even without firm data), it is
probably that all antihypertensive drugs should be given in the
smallest dosage possible consistent with blood pressure lower-
ing, especially in the relatively low-risk mild hypertensive. The
MRFIT results cannot be pooled with data from other studies to
determine benefit or risk of antihypertensive drug therapy
because, as noted, the study was not specifically a hypertension
treatment trial.
Those who argue that manifestations of coronary artery
disease have not been prevented by treatment of hypertension
must recognize, as Dr. Narins points out, that all clinical studies
to date have been of short duration, and many of them were
carried out in patients under the age of 50 or 55, in whom
cardiovascular complications are expected to be infrequent
[60]. In the HDFP study, however, the largest of the clinical
trials, a definite reduction in morbidity and mortality from
coronary artery disease was noted in the treated patients, and in
the other studies (other than the Oslo study), a trend toward
benefit was demonstrated.
I concur with the recent recommendations of the Third Joint
National Committee on Detection, Evaluation and Treatment of
High Blood Pressure: if blood pressure remains above 140/90
mm Hg after several months of nonpharmacologic manage-
ment, then specific antihypertensive therapy is indicated. The
report notes that some authorities would not treat hypertensive
patients unless diastolic pressure persistently exceeds 95 mm
Hg or unless other cardiovascular risk factors were present.
I am concerned that with the negativism occasioned by the
misinterpretation of the MRFIT data, we will forget the dramat-
ic benefits that have occurred since effective antihypertensive
therapy became available: deaths from stroke have been re-
duced by over 45% in the past 12 years [61], and a large
percentage of this reduction must be attributable to better
control of blood pressure. Progression to significant renal
disease, to congestive heart failure, or to accelerated or malig-
nant hypertension is virtually unheard of in adequately treated
hypertensives [17, 29].
I believe it is a mistake to await the development of signs of
left ventricular enlargement, funduscopic changes, or a cere-
brovascular accident before instituting antihypertensive thera-
py. Nonpharmacologic therapy might be useful as definitive
treatment in a few patients and useful as adjunctive therapy in
many. However, we now have excellent, although not ideal,
antihypertensive drugs that can lower blood pressure in most
patients and prevent vascular disease, and these should be used
ii other measures are ineffective.
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